|
Medical
Imaging Magazine
July 2003
Eye on Technology
Breast MRI: A High-Powered Tool for High-Risk Patients
by Cheryl Hall Harris, R.N.
Magnetic
resonance imaging of the breast, accepted by the FDA for use
as a supplemental tool to mammography in 1991, provides exquisitely
detailed information about very small lesions that mammography
and ultrasound often cannot detect. Of the 5,000 MRI scanners
in the United States, close to a quarter are being used for
breast exams.
While
MRI in no way is usurping mammography’s dominance in
breast cancer screening, it is shining as an adjunct for a
variety of types of high-risk patients who fit specific criteria.
The importance of highly experienced MRI breast specialists
to perform these examinations cannot be overemphasized.
The
High Risk Pool
Elizabeth
Morris, M.D., assistant radiologist, at Memorial Sloan Kettering
Cancer Center (New York, N.Y.) describes her study that determined
the usefulness of breast MRI for very select patient populations
such as women who are at increased risk for developing cancer,
including those with a strong family history or with a known
biopsy result that revealed a malignancy. Another indication
would be a woman who has completed a breast conserving “lumpectomy”
yet still has positive margins. Pre-surgical planning with
MRI informs the surgeon as to the specific size and location
of the tumor he or she is attempting to excise.
Young
women with dense breasts who have cancers that are difficult
to detect mammographically or those with a great amount of
DCIS (ductal carcinoma in situ) associated with them comprise
another class of high-risk patients for which breast MRI makes
good sense.
In
a study using a GE Medical Systems (Waukesha, Wis.) 1.5 Tesla
Horizon scanner with breast coils and contrast injection,
Morris’ group discovered several very small cancers
that were not detected with mammography. “The screening
trial found that we were able to detect cancers with MR that
weren’t detected by other means in these patients,”
Morris says. “It happened in 4 percent of the patients,
which is very high for a screening study. It went up to 8
percent if they had a personal and family history of breast
cancer. We were surprised at how high that was.” With
mammography, the detection rate is usually about 0.6 percent,
according to Morris.
Bruce
A. Porter, M.D., F.A.C.R., medical director of First Hill
Diagnostic Imaging and clinical associate professor at the
University of Washington (Seattle) explains their group uses
breast MRI solely for high-risk patients because it provides
imaging data not available through other techniques.
“Especially
using dynamic information, we commonly find and confirm tumors
that are between three and five millimeters in diameter,”
explains Porter. “Almost by definition, these would
be women whose mammograms would be negative.”
Besides
the high-risk categories of patients mentioned by Morris,
Porter cites other women who benefit from breast MRI. A small
number of breast cancers present with positive malignant axillary
nodes, but normal breast exams and mammograms. MR is capable
of locating the primary site. Women who have had breast implant
surgery improve their care from information obtained through
MR studies, too. In approximately 10 percent of women who
have biopsy-diagnosed tumors in one breast, they will have
another tumor in the contralateral breast or for women with
invasive lobular carcinoma, there is frequently a circumstance
of multifocal disease in the first breast that includes tumors
undetected by mammography or ultrasound.
 |
Fifty-five-year-old
woman with a prior LT cancer and new malignancy in the
RT breast with mixed ductal/lobular features on biopsy.
MR was used to determine the extent of the tumor and
assess the left breast for recurrance.
|
 |
Clinical
image of a fifty-seven-year-old woman with malignant right
axillary adenopathy. A 1.3-cm mass was detected by MR
in the right breast. Both images on this page courtesy
of First Hill Diagnostic Imaging. |
“When
MR is done by an experienced group, it has a very high negative
predictive value,” says Porter. “It’s one
of the best tests we have in modern medicine to say there
is nothing lurking on the other side.”
Richard Reitherman, M.D., Ph.D., director of women’s
imaging at the Newport Diagnostic Center (Newport Beach, Calif.)
concurs. “The people who do breast MRI should be breast
radiologists as opposed to MR specialists,” says Reitherman.
Because breast imaging and treatment is a very integrated
field, the radiologists who perform mammographic and ultrasound
studies, are in close contact with surgeons, pathologists
and treating physicians. And thus, Reitherman believes the
best way to increase the value of new applications in breast
MRI involves having a subspecialist perform the scans so they
become integrated into a multimodality, multispecialty application
for breast cancer diagnosis and treatment.
Paul D. Friedman, D.O., attending radiologist and breast interventionalist
at St. Barnabas Medical Center in Livingston, N.J., agrees
with this multidisciplinary approach. They are using their
Philips Medical Systems (Bothell, Wash.) Intera 1.5 Tesla
scanner to image high-risk patients for diagnostic purposes
and for needle localization for biopsy of suspicious lesions.
“We correlate all of the mammographic films, ultrasound
and any outside films and then we do the MRI,” Friedman
says. They have dedicated breast specialists and mammographers
reading the films.
Their scanner is equipped with new SENSE technology developed
by Philips designed to image more quickly with thinner slices
to improve resolution. Friedman says that allows them to image
both breasts simultaneously, with a typical study taking 25
minutes to complete.
SENSE (SENSitivity Encoding) is a technique based on the use
of multiple RF coils and receivers. Improvements in acquisition
speed — greater than that possible through conventional
methods involving increased gradient strength — is intended
to improve efficiency for this real-time imaging modality.
The Essentials
There have been two issues of paramount importance in providing
appropriate MR studies for patients with breast cancer. The
first is the need to use a system that is capable of acquiring
both breasts simultaneously. The second is to provide images
in the sagittal plane because mammographers are accustomed
to reviewing images and seeing breast structures in this way.
GEMS
addresses these issues through an application called EXCITE,
which has just been applied to their breast imaging system.
Prior to the launch of this new capability, radiologists scanned
one breast at a time, with an overnight interim period to
allow contrast material to be metabolized out of the patient’s
body. Huge amounts of data may be acquired in one of these
studies, up to hundreds of images in a sequence or an exam,
which presents workflow and image reconstruction issues.

Confirma’s
new CADstream produces a 3D volume rendering of a pre-contrast
image with tumors highlighted.
Mona
Theobald, GEMS general manager Americas MR sales and marketing
says, “This is new technology and a new data pipeline
in the MR scanner that allows this system to scan data much
more rapidly at high resolution.” The system is capable
of reconstructing 400 images per second, enabling bilateral
breast imaging in the sagittal plane with contrast injections
and high spatial resolution imaging. Any installed GEMS MR
scanner can be upgraded to include EXCITE technology, and
Theobald says the breast application runs the most efficiently
using this enhancement.
Another
question that often arises is the optimum level of field strength
of the magnet to use in breast MRI.
Porter
says they have found their Siemens Harmony 1.0 Tesla MR scanner
with dedicated breast coils provides images with few artifacts
and reliable high-resolution images to deliver the clinical
information they require.
“At
higher field strengths, motion sensitivity becomes greater,
chemical shift becomes greater, and inhomogeneity of the radiofrequency
field becomes more of an issue,” explains Porter who
describes that imaging the breast is like driving on ice —
it requires more finesse than raw power. He believes that
gradient amplifiers are a more critical component. In his
courses to teach clinicians MR breast imaging techniques,
he finds that those with a higher field strength magnet may
face challenges he does not.
Helmuth
Schultze-Haakh, MR collaborations manager of the Pacific Region
for Siemens Medical Solutions (Malvern, Pa.), explains that
over the past decade, two approaches to breast MR were developed.
The first, pioneered by radiologists in Germany, employs injection
of a bolus of gadolinium to quantify and display uptake and
washout of the contrast through the vasculature of the tumor.
The second technique, developed in the U.S., takes advantage
of an image software enhancement called Rotating Delivery
of Excitation Off-resonance (RODEO) to improve the resolution
of morphologic features of the tumor being studied.Porter
explains that his group employs a hybrid approach that incorporates
both techniques for breast imaging to produce high-resolution
morphologic imaging with dynamic kinetic information from
contrast studies.
By
combining both techniques, clinicians increase the specificity
required for making treatment decisions. Porter describes
that when they image women with a known tumor in one breast,
between 3 and 10 percent will have a tumor in the contralateral
breast that is undetected on mammography. This information
has a high impact on the management of that patient.
Typically,
a pre-contrast image acquisition is followed by an intravenous
injection and then five one-minute acquisitions. Comparing
data between all of the single acquisitions produces a dynamic
curve evaluation to identify the way a particular lesion enhances
over all the time points. Reitherman, who uses a Siemens Symphony
1.5 Tesla scanner with breast coils, describes the characteristics
of many malignancies including those of the breast. Tumor
angiogenesis occurs in all organs of the body, and involves
the formation of abnormal blood vessels used to nourish the
tumor. The features of this vasculature allow one aspect of
specificity in diagnosis.
“Tumor
angiogenic vessels have two basic abnormalities that we monitor,”
says Reitherman. “The vessels are more permeable and
the gadolinium leaks out more quickly, and the vessels characteristically
form arterial-venous malformations which makes the blood wash
out more quickly.”
The classic malignant curve during an MR study would show
a high initial uptake within the first 60 to 90 seconds, and
then a “wash out” where the curve reverses itself
and the clinician sees a drop in the absolute intensity within
the tumor volume.The second type of curve is one that enhances
rapidly, but after the initial 60 to 90 seconds, it plateaus.
The third kind of dynamic curve is one where after the initial
phase, it continues to increase over time.
However,
many cancers do not exhibit the high washout curve, according
to Reitherman. So they couple the findings from the dynamic
study with high-resolution images that reveal the morphology
of the tumor mass, and define whether the outer edges are
smooth or fuzzy. Reitherman is using a new software tool scheduled
for release this month, for interpreting these dynamic curves.
A product of Confirma Inc. (Kirkland, Wash.), CADstream performs
processing functions that physicians currently are accomplishing
through manual calculations.
Mary
Gatewood, product manager for CADstream, describes this approach
as an efficiency tool for breast MRI.
“It
does things like subtraction, multiplanar formats, …
within about a 15-minute processing time,” explains
Gatewood. Other than the autoprocessing capability, other
features assist the physician in interpreting images. One
segment of this application is designed to register images
to compensate for any patient movement during the study. Because
these studies involve the acquisition of a series of images,
even breathing could decrease the specificity of interpretation.
The image registration feature provides a summary of whether
or not major correction was required, aler ting the reader
to that fact.
The
product provides an interactive tool, where the physician
can run the computer mouse over an image and see the curve
for any point on that image. Currently, physicians ask their
technicians to find an area where they want to see the curve,
and perform manual calculations for the information.“
One
of the most popular features about the product is the angiogenesis
map which is a color overlay that corresponds to contrast
uptake and washout,” says Gatewood. Employing three
different colors to denote the variations in uptake and washout
over a specified period of time, the physician gains valuable
information about unique tumor qualities.Reitherman describes
that for a new user, someone who has not been doing breast
MRIs for a long time, that CADstream offers straightforward
methods of analyzing images that simplify the process.
Tissue
Sampling: A Vital Function
Because
MRI is capable of identifying lesions that are undetected
with other imaging techniques, being able to use MR guidance
for needle locations and tissue sampling is critical to the
effective and efficient use of this modality in managing patients
with breast cancer.
“We’ve
done more than 50 MRI needle localizations on lesions that
were occult to mammography and ultrasonography,” says
Friedman. These were lesions that would have been missed without
MRI, and about 30 percent of the women had either cancer or
a high-risk lesion. They had MRI exams because they fit into
high-risk categories of patients such as those with a family
history or other factor, but their cancer would have been
missed until it had spread further if their care had been
directed with just the usual imaging studies.
Xiaoming
Chen, M.D., Ph.D. assistant professor in the department of
radiology at the University of Washington, has been involved
in a study where they used a standard 14-gauge stainless steel
core biopsy needle to obtain tissue samples.
“This
new method uses an MR-compatible coaxial device which consists
of an outer titanium sheath and an inner titanium stylet to
target the lesion,” says Chen. The titanium sheath is
inserted into the breast tissue and imaged using their GEMS
1.5 Tesla scanner with dedicated breast coils. Once they are
sure the sheath is in contact with the lesion, the patient
is moved two meters away from the bore of the magnet where
the sample is obtained. They do not have any problems with
the stainless steel needle being attracted by the magnet at
this distance.
At
the University of Washington, they use MR prior to the first
surgery to look for multifocal or contralateral disease because
that helps to decide whether breast-conserving surgery is
an option, or if a mastectomy would be the best way to proceed.
They can use this technique to sample any lesions they suspect
of being cancerous.
Suros
Surgical Systems Inc. (Indianapolis, Ind.) launched a new
product in May: the ATEC®
breast biopsy system that is designed to enable MR-guided
biopsies within 30 minutes. This vacuum-assisted breast biopsy
device is pneumatically powered (air driven) which means it
is MRI compatible. Zeeshan Shah, M.D., associate professor
of radiology at Indiana University School of Medicine relates
that every patient who they have used this system to obtain
tissue samples on has been amazed by how quick and how easy
the biopsy was. Using the ATEC®
system, tissue samples can be acquired every 3.5 seconds,
10 times faster than with any other vacuum-assisted breast
biopsy system.
Timothy
Goedde, M.D., medical director of Suros Surgical, explains
that since the system is air driven, and there are no electric
cables in the room, they use a metal 12-gauge needle inside
a plastic housing to obtain the sample. This provides large
enough samples for analysis.
The
Drawbacks
Despite
the many advantages, there are a few drawbacks to the use
of MRI for imaging the breast. Unlike mammography, this modality
is unable to image calcifications that can indicate breast
cancer. MRI is a more expensive imaging technique at nearly
10 times the cost of mammography. Some patients experience
claustrophobia in these scanners, and MRI can produce a moderate
number of false-positive findings which result in biopsies
for benign lesions. However, experienced breast MRI practitioners
believe the benefits far outweigh the drawbacks.
Conclusion
MRI
of the breast has become the standard of practice in many
women’s imaging centers to improve detection of very
small lesions. The growth in the use of this modality increased
45 percent between 2001 and 2002. With advances in the scanners
and their image processing software, and the development of
new devices to enable faster and improved biopsy techniques,
this modality likely will increase in popularity across the
country in the management of patients with breast cancer.
Medical
Imaging
MWC / Allied Healthcare Group
6701 Center Drive West, #450
Los Angeles, CA 90045
(310) 642-4400 Office
(310) 641-4444 Fax
Copyright © 2003 MWC/Allied Healthcare
Group. All rights reserved.
|